Developmentally regulated inhibition of cell cycle progression by glucocorticoids through repression of cyclin a transcription in primary osteoblast cultures

Journal of Cellular Physiology

Volumn 226, Issue 4, 2011, Pages 991-998

  Gabet, Yankel ^a   Noh, Tommy ^a   Lee, Christopher ^a   Frenkel, Baruch ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; ACTIVATING TRANSCRIPTION FACTOR 4; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN A; CYCLIN D1; GLUCOCORTICOID; MESSENGER RNA; MYC PROTEIN; WNT PROTEIN;

ANIMAL CELL; ARTICLE; BINDING SITE; BONE DEVELOPMENT; CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CONTROLLED STUDY; GENE EXPRESSION; MINERALIZATION; MITOGENESIS; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TREATMENT DURATION;

ACTIVATING TRANSCRIPTION FACTOR 4; ANIMALS; ANIMALS, NEWBORN; CELL CYCLE; CELL LINEAGE; CELLS, CULTURED; CYCLIN A; CYCLIN D1; DEXAMETHASONE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GLUCOCORTICOIDS; MICE; OSTEOBLASTS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; WNT PROTEINS;

EID: 79251507984     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22412     Document Type: Article

References (49)

1. Adams CM. 2007. Role of the transcription factor ATF4 in the anabolic actions of insulin and the anti-anabolic actions of glucocorticoids. J Biol Chem 282:16744-16753.
2. Bellows CG, Aubin JE, Heersche JN, Antosz ME. 1986. Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif Tissue Int 38:143-154.
3. Buttgereit F, Saag KG, Cutolo M, da Silva JA, Bijlsma JW. 2005. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: Focus on the treatment of rheumatoid arthritis. Scand J Rheumatol 34:14-21.
4. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. 2007. Glucocorticoid-induced osteoporosis: Pathophysiology and therapy. Osteoporos Int 18:1319-1328.
5. Chen TL, Aronow L, Feldman D. 1977. Glucocorticoid receptors and inhibition of bone cell growth in primary culture. Endocrinology 100:619-628.
6. Chen TL, Cone CM, Feldman D. 1983. Glucocorticoid modulation of cell proliferation in cultured osteoblast-like bone cells: Differences between rat and mouse. Endocrinology 112:1739-1745.
7. Cheng L, Li L, Qiao X, Liu J, Yao X. 2007. Functional characterization of the promoter of human kinetochore protein HEC1: Novel link between regulation of the cell cycle protein and CREB family transcription factors. Biochim Biophys Acta 1769:593-602.
8. DasGupta R, Fuchs E. 1999. Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development 126:4557-4568.
9. Delany AM, Canalis E. 1995. Transcriptional repression of insulin-like growth factor I by glucocorticoids in rat bone cells. Endocrinology 136:4776-4781.
10. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. 1997. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 89:747-754.
11. Fortunati D, Reppe S, Fjeldheim AK, Nielsen M, Gautvik VT, Gautvik KM. 2010. Periostin is a collagen associated bone matrix protein regulated by parathyroid hormone. Matrix Biol (Epub ahead of print).
12. Fragale A, Tartaglia M, Bernardini S, Di Stasi AM, Di Rocco C, Velardi F, Teti A, Battaglia PA, Migliaccio S. 1999. Decreased proliferation and altered differentiation in osteoblasts from genetically and clinically distinct craniosynostotic disorders. Am J Pathol 154:1465-1477.
13. Gabet Y, Baniwal SK, Leclerc N, Shi Y, Kohn-Gabet AE, Cogan J, Dixon A, Chavez M, Guo L, Turman JE, Frenkel B. 2010. Krox20/EGR2 deficiency accelerates cell growth and differentiation in the monocytic lineage and decreases bone mass. Blood. Prepublished online August 17, 2010; DOI: 2010.1182/blood-2010-2001-263830.
14. Glass DA II, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G. 2005. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-764.
15. Glass DA II, Karsenty G. 2006. Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr Top Dev Biol 73:43-84.
16. Hall BK, Miyake T. 2000. All for one and one for all: Condensations and the initiation of skeletal development. BioEssays 22:138-147.
17. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. 1998. Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512.
18. Imasato A, Desbois-Mouthon C, Han J, Kai H, Cato AC, Akira S, Li JD. 2002. Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of toll-like receptor 2. J Biol Chem 277:47444-47450.
19. Jakoby M, Schnittger A. 2004. Cell cycle and differentiation. Curr Opin Plant Biol 7:661-669.
20. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC. 2001. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 20:7108-7116.
21. Katabami M, Donninger H, Hommura F, Leaner VD, Kinoshita I, Chick JF, Birrer MJ. 2005. Cyclin A is a c-Jun target gene and is necessary for c-Jun-induced anchorage-independent growth in RAT1a cells. J Biol Chem 280:16728-16738.
22. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL. 2006. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116:2152-2160.
23. Leclerc N, Luppen CA, Ho VV, Nagpal S, Hacia JG, Smith E, Frenkel B. 2004. Gene expression profiling of glucocorticoid-inhibited osteoblasts. J Mol Endocrinol 33:175-193.
24. Manolagas SC, Weinstein RS. 1999. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14:1061-1066.
25. Masuoka HC, Townes TM. 2002. Targeted disruption of the activating transcription factor 4 gene results in severe fetal anemia in mice. Blood 99:736-745.
26. Migliaccio S, Brama M, Fornari R, Greco EA, Spera G, Malavolta N. 2007. Glucocorticoid-induced osteoporosis: An osteoblastic disease. Aging Clin Exp Res 19:5-10.
27. Miguel SM, Namdar-Attar M, Noh T, Frenkel B, Bab I. 2005. ERK1/2-activated de novo Mapkapk2 synthesis is essential for osteogenic growth peptide mitogenic signaling in osteoblastic cells. J Biol Chem 280:37495-37502.
28. Noh T, Gabet Y, Cogan J, Shi Y, Tank A, Sasaki T, Criswell B, Dixon A, Lee C, Tam J, Kohler T, Segev E, Kockeritz L, Woodgett J, Muller R, Chai Y, Smith E, Bab I, Frenkel B. 2009. Lef1 haploinsufficient mice display a low turnover and low bone mass phenotype in a gender- and age-specific manner. PLoS ONE 4:e5438.
29. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. 2005. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329:177-181.
30. Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R. 2004. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: Novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 318:259-264.
31. Parker BJ, Bruce IN. 2007. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 16:387-393.
32. Pulverer BJ, Fisher C, Vousden K, Littlewood T, Evan G, Woodgett JR. 1994. Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 9:59-70.
33. Rogatsky I, Trowbridge JM, Garabedian MJ. 1997. Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms. Mol Cell Biol 17:3181-3193.
34. Rubin MR, Bilezikian JP. 2002. Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: A re-examination of the evidence. J Clin Endocrinol Metab 87:4033-4041.
35. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. 2000. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14:2501-2514.
36. Shankar DB, Cheng JC, Kinjo K, Federman N, Moore TB, Gill A, Rao NP, Landaw EM, Sakamoto KM. 2005. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell 7:351-362.
37. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. 1999. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96:5522-5527.
38. Smith E, Coetzee GA, Frenkel B. 2002. Glucocorticoids inhibit cell cycle progression in differentiating osteoblasts via glycogen synthase kinase-3beta. J Biol Chem 277:18191-18197.
39. Smith E, Frenkel B. 2005. Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3beta-dependent and -independent manner. J Biol Chem 280:2388-2394.
40. Smith E, Redman RA, Logg CR, Coetzee GA, Kasahara N, Frenkel B. 2000. Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle. Dissociation of cyclin A-cyclin-dependent kinase 2 from E2F4-p130 complexes. J Biol Chem 275:19992-20001.
41. Song WJ, Schreiber WE, Zhong E, Liu FF, Kornfeld BD, Wondisford FE, Hussain MA. 2008. Exendin-4 stimulation of cyclin A2 in beta-cell proliferation. Diabetes 57:2371-2381.
42. Sunters A, Thomas DP, Yeudall WA, Grigoriadis AE. 2004. Accelerated cell cycle progression in osteoblasts overexpressing the c-fos proto-oncogene: Induction of cyclin A and enhanced CDK2 activity. J Biol Chem 279:9882-9891.
43. Swolin D, Brantsing C, Matejka G, Ohlsson C. 1996. Cortisol decreases IGF-I mRNA levels in human osteoblast-like cells. J Endocrinol 149:397-403.
44. Tanaka T, Tsujimura T, Takeda K, Sugihara A, Maekawa A, Terada N, Yoshida N, Akira S. 1998. Targeted disruption of ATF4 discloses its essential role in the formation of eye lens fibres. Genes Cells 3:801-810.
45. Tetsu O, McCormick F. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426.
46. Wang FS, Lin CL, Chen YJ, Wang CJ, Yang KD, Huang YT, Sun YC, Huang HC. 2005. Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology 146:2415-2423.
47. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. 1998. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274-282.
48. Wong GL. 1979. Basal activities and hormone responsiveness of osteoclast-like and osteoblast-like bone cells are regulated by glucocorticoids. J Biol Chem 254:6337-6340.
49. Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, Li L, Brancorsini S, Sassone-Corsi P, Townes TM, Hanauer A, Karsenty G. 2004. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology: Implication for Coffin-Lowry syndrome. Cell 117:387-398.